[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]
| Autor: | G, von Minckwitz, G, Raab, M, Schütte, J, Hilfrich, J U, Blohmer, B, Gerber, S D, Costa, E, Merkle, H, Eidtmann, D, Lampe, C, Jackisch, A, du Bois, A H, Tulusan, G, Gademann, H P, Sinn, A, Caputo, E, Graf, M, Kaufmann |
|---|---|
| Jazyk: | němčina |
| Rok vydání: | 2001 |
| Předmět: |
Paclitaxel
Carcinoma Breast Neoplasms Docetaxel Survival Analysis Neoadjuvant Therapy Tamoxifen Clinical Trials Phase II as Topic Treatment Outcome Clinical Trials Phase III as Topic Chemotherapy Adjuvant Doxorubicin Germany Antineoplastic Combined Chemotherapy Protocols Humans Multicenter Studies as Topic Female Taxoids Randomized Controlled Trials as Topic |
| Zdroj: | Zentralblatt fur Gynakologie. 123(9) |
| ISSN: | 0044-4197 |
| Popis: | The German Adjuvant Breast Cancer Study Group (GABG) conducts trials of preoperative chemotherapy in patients with primary breast cancer using a combination of doxorubicin and docetaxel (ADoc). -We conducted a parallel-grouped phase IIa-study with 42 patients with a conventionally dosed and a dose-dense ADoc-schedule (4 cycles of Doxorubicin 50 mg/m(2), Docetaxel 75 mg/m(2) i. v. day 1, q day 15 or 22; G-CSF day 3-15 only for the dose-dense schedule) and a randomized phase IIb-study (GEPARDO-Study) with 250 patients with ADoc +/- Tamoxifen. Biological factors were determined immunohistochemically on 197 core biopsies before treatment. A comparison to a sequential AC-Doc regimen including 913 patients has been completed recently. -ADoc can be applicated on schedule in 93 % of all patients. The dose-dense regimen shows a tendency to more toxicity but also to more efficacy. The rate of complete pathological remissions (pCR) was 9.7 %. No difference was found between chemo- and chemoendocrine treatment. Clinically negative lymphnodes and a negative estrogen receptor status is predictive for a higher pCR-rate. To date no differences in toxicity could be found between ADoc and AC-Doc. -The dose-dense ADoc regimen is well tolerated and highly effective as preoperative therapy of breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|